KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $164.0 million.

  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity rose 73.96% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.2 million, marking a year-over-year increase of 54.27%. This contributed to the annual value of $164.0 million for FY2024, which is 39.88% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Liabilities and Shareholders Equity stood at $164.0 million, which was up 39.88% from $117.2 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $167.3 million in FY2021 and a low of $110.4 million during FY2020.
  • For the 3-year period, Rigel Pharmaceuticals' Liabilities and Shareholders Equity averaged around $138.5 million, with its median value being $134.3 million (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first dropped by 25.20% in 2020, then skyrocketed by 51.60% in 2021.
  • Over the past 5 years, Rigel Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $110.4 million in 2020, then soared by 51.60% to $167.3 million in 2021, then fell by 19.75% to $134.3 million in 2022, then declined by 12.70% to $117.2 million in 2023, then surged by 39.88% to $164.0 million in 2024.